| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0785 | Auh-6-96 | Novel inhibitor of JAK/STAT signaling, inhibiting both constitutive and interleukin-6-induced STAT3 phosphorylation, selectively affecting cell viability only of cancer cells harboring aberrant JAK/STAT signaling |
|
| DCC0786 | aureusidin | Potent inhibitor of HCV RdR |
|
| DCC0787 | Aurka-in-12 | Novel AURKA inhibitor, reducing clonogenicity, arresting the cell cycle at the G2/M phase, and inducing caspase-mediated apoptotic cell death in HCT116 human colon cancer cells |
|
| DCC0788 | Auromomycin | Natural antibiotic |
|
| DCC0789 | Aurone-4-3 | Novel inhibitor of AChE, suppressing Aβ aggregation, protecting Caenorhabditis elegans against Aβ- and 6-OHDA-induced neurotoxicities dose-dependently |
|
| DCC0790 | Aurone-51 | Potent inhibitor of HCV RdR |
|
| DCC0791 | Aurora A Inhibitor-9 | Novel small 4 integrin antagonist, preventing the development of experimental colitis in mice. |
|
| DCC0792 | Aurora-in-1 | Novel potent ATP-competitive inhibitor of Aurora A/B/C (5.6/18.4/24.6 nM) |
|
| DCC0793 | Austrocortirubin | Novel DNA damage inducer during G0/G1, S, and G2 cell cycle phases via a mechanism unique from other DNA damaging agents |
|
| DCC0794 | Authipyrin | Novel autophagy inhibitor, targeting mitochondrial complex I directly, leading to the potent inhibition of mitochondrial respiration as well as autophagy |
|
| DCC0795 | Autoinducer-2 | Unique signaling molecule used in quorum sensing |
|
| DCC0796 | Autophagy Inhibitor 6k | Novel inhibitor of autophagy, promoting metabolic stress within the tumour microenvironment and potentiating the effect of cytostatics in combination therapy |
|
| DCC0797 | Autophagy Inhibitor C1 | Novel anticancer agent, exhibiting potential cytotoxicity and inhibiting autophagy in hepatocellular carcinoma (HCC) cells |
|
| DCC0798 | Auy954 | Monoselective agonist of the S1P(1) receptor |
|
| DCC0799 | Av-11324-5 | Novel USP30 inhibitor |
|
| DCC0800 | Av-11324-75 | Novel USP28 inhibitor |
|
| DCC0801 | Av-15a | Novel, highly potent p53-MDM2 inhibitor with an IC50 value of 0.08 nmol/L, displaying excellent oral efficacy in the human SJSA1-based xenograft model. |
|
| DCC0802 | Av-233 | First-in-class allosteric inhibitor of respiratory syncytial virus (RSV), blocking RNA elongation by the respiratory syncytial virus polymerase complex |
|
| DCC0803 | Av-9606-129 | Novel USP28 inhibitor |
|
| DCC0804 | Av-9606-41 | Novel selective USP7 inhibitor (USP7 IC50 9 μM; USP8 >50μM) |
|
| DCC0805 | Av-9606-99 | Novel USP28 inhibitor |
|
| DCC0806 | Avarofloxacin | The fifth-generation fluoroquinolone with in vitro coverage of community-acquired bacterial pneumonia (CABP) pathogens, atypical respiratory pathogens, multidrug-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus |
|
| DCC0807 | Ave0991 | Novel non-peptide Ang-(1-7) mimetic, inhibiting perivascular inflammation, through the reduction of chemokine expression in pVAT, as well as through direct actions on monocytes/macrophages inhibiting their activation |
|
| DCC0808 | Ave-0991 Sodium Salt | Novel angiotensin-(1-7) Mas receptor agonist |
|
| DCC0809 | Ave6971 | Novel antistaphyloccocal agent, attenuating inhibition of hERG potassium channel current |
|
| DCC0810 | Avicenol A | Cancer chemoprevebtive agent |
|
| DCC0811 | Avoenin | Natural potent antienterovirus D68 (anti-EV-D68) agent |
|
| DCC0812 | Avx002 | Novel cytosolic phospholipase A2 group IVA (cPLA2α) inhibitor, displaying potent anti-inflammatory activity and disease-modifying properties in cellular and in vivo models |
|
| DCC0813 | Avx-13616 | Potent broad spectrum antibacterial agent, particularly against drug-resistant Staphylococcus pathogens |
|
| DCC0814 | avβ3 Inhibitor [351421-54-0] | Novel potent and selective αvβ3 integrin inhibitor |
|
